Spyre Therapeutics (SYRE) Accumulated Expenses (2015 - 2026)

Spyre Therapeutics' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $29.2 million for Q1 2026.

• Quarterly Accumulated Expenses rose 34.81% year-over-year to $29.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.2 million (up 34.81% YoY) and the FY2025 annual result came in at $26.9 million, down 2.76% from the prior year.
• Accumulated Expenses was $29.2 million for Q1 2026 at Spyre Therapeutics, up from $26.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $29.2 million in Q1 2026 and bottomed at $2.4 million in Q1 2022.
• A 5-year average of $15.3 million and a median of $13.2 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 70.56% — and 2024, when it jumped 655.83%.
• Spyre Therapeutics' Accumulated Expenses stood at $12.8 million in 2022, then climbed by 2.11% to $13.1 million in 2023, then jumped by 111.41% to $27.7 million in 2024, then slipped by 2.76% to $26.9 million in 2025, then increased by 8.21% to $29.2 million in 2026.
• Business Quant data shows SYRE's Accumulated Expenses at $29.2 million in Q1 2026, $26.9 million in Q4 2025, and $23.8 million in Q3 2025.